Backed by bil­lion­aire Mike Platt, En­gi­tix scores an­oth­er deal with Take­da to go af­ter IBD

En­gi­tix is on a roll.

The British biotech backed by bil­lion­aire hedge fund man­ag­er Mike Platt se­cured an ex­pan­sion on its ear­li­er Take­da deal, it an­nounced Tues­day morn­ing, win­ning a new promise of up to $300 mil­lion in mile­stones. En­gi­tix and Take­da will use the time to de­vel­op new treat­ments for IBD, in­clud­ing Crohn’s dis­ease and ul­cer­a­tive col­i­tis.

Tues­day’s deal al­so in­clud­ed an up­front pay­ment, the size of which was not dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER